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Abstract
Background: Microglia provide continuous immune surveillance of the CNS and upon activation rapidly change 
phenotype to express receptors that respond to chemoattractants during CNS damage or infection. These activated 
microglia undergo directed migration towards affected tissue. Importantly, the molecular species of chemoattractant 
encountered determines if microglia respond with pro- or anti-inflammatory behaviour, yet the signaling molecules 
that trigger migration remain poorly understood. The endogenous cannabinoid system regulates microglial migration 
via CB2 receptors and an as yet unidentified GPCR termed the 'abnormal cannabidiol' (Abn-CBD) receptor. Abn-CBD is a 
synthetic isomer of the phytocannabinoid cannabidiol (CBD) and is inactive at CB1 or CB2 receptors, but functions as a 
selective agonist at this Gi/o-coupled GPCR. N-arachidonoyl glycine (NAGly) is an endogenous metabolite of the 
endocannabinoid anandamide and acts as an efficacious agonist at GPR18. Here, we investigate the relationship 
between NAGly, Abn-CBD, the unidentified 'Abn-CBD' receptor, GPR18, and BV-2 microglial migration.
Results: Using Boyden chamber migration experiments, yellow tetrazolium (MTT) conversion, In-cell Western, qPCR 
and immunocytochemistry we show that NAGly, at sub-nanomolar concentrations, and Abn-CBD potently drive 
cellular migration in both BV-2 microglia and HEK293-GPR18 transfected cells, but neither induce migration in HEK-
GPR55 or non-transfected HEK293 wildtype cells. Migration effects are blocked or attenuated in both systems by the 
'Abn-CBD' receptor antagonist O-1918, and low efficacy agonists N-arachidonoyl-serine and cannabidiol. NAGly 
promotes proliferation and activation of MAP kinases in BV-2 microglia and HEK293-GPR18 cells at low nanomolar 
concentrations - cellular responses correlated with microglial migration. Additionally, BV-2 cells show GPR18 
immunocytochemical staining and abundant GPR18 mRNA. qPCR demonstrates that primary microglia, likewise, 
express abundant amounts of GPR18 mRNA.
Conclusions: NAGly is the most effective lipid recruiter of BV-2 microglia currently reported and its effects mimic those 
of Abn-CBD. The data generated from this study supports the hypothesis that GPR18 is the previously unidentified 
'Abn-CBD' receptor. The marked potency of NAGly acting on GPR18 to elicit directed migration, proliferation and 
perhaps other MAPK-dependent phenomena advances our understanding of the lipid-based signaling mechanisms 
employed by the CNS to actively recruit microglia to sites of interest. It offers a novel research avenue for developing 
therapeutics to elicit a self-renewing population of neuroregenerative microglia, or alternatively, to prevent the 
accumulation of misdirected, pro-inflammatory microglia which contribute to and exacerbate neurodegenerative 
disease.McHugh et al. BMC Neuroscience 2010, 11:44
http://www.biomedcentral.com/1471-2202/11/44
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Background
In normal brain, microglia possess a characteristic rami-
fied morphology which facilitates continuous immune
surveillance [1,2]. When the CNS is damaged or infected,
microglia undergo a phenotypic shift, altering their shape
and expressing receptors that recognize endogenous and
exogenous chemoattractants [3]. Receptor-initiated sig-
naling cascades enable microglia to execute rapid,
directed migration towards affected tissue [4]. Depending
on the molecular species encountered, altered gene
expression further adjusts the microglial phenotype
towards pro- or anti-inflammatory [5,6]. Directed micro-
glial migration is a major CNS defense and provides for
homeostatic maintenance and tissue repair. Dysregula-
tion of migration and phenotype leads to excessive pro-
inflammatory and cytotoxic responses implicated in sev-
eral neurodegenerative diseases, including multiple scle-
rosis and Alzheimer's disease [7-11]. Despite their
importance, the mechanisms controlling microglial
migration and phenotype remain poorly understood.
Endogenous cannabinoid signaling regulates microglial
migration via CB2 receptors and an unidentified GPCR,
the 'abnormal cannabidiol' (Abn-CBD) receptor [12,13]
(a.k.a. the 'endothelial anandamide' receptor or CBx). The
pharmacology of endogenous and phytocannabinoids is
complex; well documented pharmacological evidence
supports multiple cannabinoid receptor subtypes. Two
have been cloned, CB1 and CB2, whereas others discrimi-
nated using pharmacological and genetic tools remain to
be identified at the molecular level [14-17]. The 'Abn-
CBD' receptor is the most prominent of these receptors
and has been implicated in endothelium-dependent vaso-
dilation in isolated resistance vessels, haemodynamic
responses and modulation of microglial, endothelial and
glioma cell migration [12,13,15,16,18-21]. Its defining
characteristics are: activation by two synthetic isomers of
cannabidiol (CBD), Abn-CBD and O-1602, which are
inactive at CB1 and CB2 [15,16,18]. Other agonists include
anandamide (AEA) and 2-arachidonoyl glycerol (2-AG),
but not palmitoyl ethanolamide (PEA) [13,18,22]. CBD
and N-arachidonoyl serine (ARA-S) are very low efficacy
agonists behaving as partial agonists/antagonists depend-
ing on receptor expression levels; whereas another CBD
analogue, O-1918, and rimonabant act as antagonists,
a l t h o u g h  r i m o n a b a n t  d o e s  s o  o n l y  m o d e r a t e l y
[13,17,19,23]. The receptor is Gi/o-coupled and its activa-
tion stimulates p44/42 mitogen-activated protein kinase
(MAPK) [13,19].
N-arachidonoyl glycine (NAGly) is an endogenous
metabolite of AEA, differing by the oxidation state of the
carbon β to the amido nitrogen - a modification that
drastically reduces its activity at CB1 and CB2 [24]. A
wealth of data demonstrates that NAGly triggers anti-
nociceptive and anti-inflammatory activities [25]. Several
parallel pathwa ys ha ve been described for its synthesis
[ 2 5 ] ,  i t  i s  h y d r o l y z e d  b y  f a t t y  a c i d  a m i d e  h y d r o l a s e
(FAAH) [25], and is a high affinity ligand for Gi/o-coupled
GPR18 [26] and a partial agonist of Gq/11-coupled GPR92
receptors [27].
Here, using the immortalized primary microglial cell
line (BV-2) [28], which have been shown to retain most of
the morphological, phenotypical and functional proper-
ties described for freshly isolated active microglial cells
[13,28], we investigate the hypothesis that NAGly and
Abn-CBD regulate microglial migration through GPR18;
identifying GPR18 as the unknown 'Abn-CBD' receptor.
W e  d e m o n s t r a t e  t h a t  N A G l y  i s  t h e  m o s t  p o t e n t  p r o -
migratory lipid for BV-2 microglia described to date and
its effects mimic those of Abn-CBD at the 'Abn-CBD'
receptor. Our data support the hypothesis that GPR18 is
the 'Abn-CBD' receptor and suggest that NAGly is a pri-
mary means for initiating directed microglial migration
in the CNS.
Results
NAGly potently induces directed microglial migration
Directed microglial migration and phenotypic modifica-
tions are known to be stimulated by factors including
bacterial peptides, lysophospholipids and endocannabi-
noids [13,29,30]. Therefore, we compared NAGly-
induced BV-2 microglial migration with N-formyl-methi-
onine-leucine-phenylalanine (fMLP) and archidonoyl
lysophophatidic acid (LPA), chemotactic ligands released
under conditions of brain injury or infection [31,32].
NAGly potently induced concentration-dependent
migration, and elicited a response twice that produced by
1 μM fMLP or LPA at NAGly concentrations of 0.17 nM
and 0.08 nM, respectively (Figure 1A).
Chemotaxis (directed migration) is the process
whereby cells sense soluble molecules and purposely
advance along a concentration gradient to their source.
This is in contrast to chemokinesis (stimulated random
motion), where cells experience spontaneous cytoskeletal
polymerization which prompts indiscriminate meander-
ing. Checkerboard analysis offers a means to differentiate
migratory behaviour between chemotaxis and chemoki-
nesis, and is based on disrupting the concentration gradi-
ent of a pro-migratory ligand. Indiscriminate cell
migration across a filter membrane will remain unaf-
fected by the absence of a concentration gradient.
Whereas directed cell migration is prevented by the
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absence of the guidance cue derived from the concentra-
tion gradient. Checkerboard analysis of NAGly revealed
BV-2 microglia exhibit chemotaxis, and purposely
advance towards the source of NAGly in a directed man-
ner (Figures 1A &1B). A low basal level of chemokinesis
was observed, which is the case with all established
chemoattractants (Figure 1B).
As NAGly undergoes hydrolysis via FAAH to form AA
and glycine [25], both of which are signaling molecules in
their own right, we investigated whether the NAGly-
induced response was due to its metabolism to either of
these products. 1 μM NAGly produced a migratory
response (% of fMLP migration) of 435.9% ± 36.9% com-
pared to 22.4% ± 2.9% for AA, and -15.4% ± 5.4% for gly-
cine; these values are significantly different (P < 0.001
compared to 1 μM NAGly; one-way ANOVA; n = 3). This
indicates that neither AA nor glycine can account for the
migratory response produced in BV-2 microglial cells by
NAGly.
In 2003, Walter et al described endocannabinoid sys-
tem involvement in recruiting microglia toward dying
neurons: pathological stimulation of neurons and micro-
glia led to a dramatic and selective increase in 2-AG pro-
duction which triggered microglial migration by engaging
CB2 and 'Abn-CBD' receptors [13]. Therefore, we next
compared NAGly-induced migration to various endocan-
nabinoids, endogenous lipids and compounds relevant to
'Abn-CBD' receptor pharmacology to compare the
potency of each of these compounds to induce migration
(Figures 2A &2B). A response double that of 1 μM fMLP
was elicited by the following concentrations of ligand:
0.17 nM NAGly, 0.27 nM O-1602, 5.2 nM 2-AG, 13.1 nM
Abn-CBD and 123 nM AEA (Figure 2A). PEA (the endog-
enous AEA analogue), palmitoyl glycine (PALGly; the
endogenous NAGly analogue), and L-α-lysophosphati-
dylinositol (LPI) all exerted a minimal, concentration-
independent stimulation of migration. The mean migra-
tion achieved for these compounds across a concentra-
tion range of 0.1 nM - 10 μM being 12.5% ± 3.5% (PEA; n
= 3), 16.9% ± 3.9% (PALGly; n = 3), and 23.5% ± 4.7%
(LPI; n = 3). Thus, NAGly potently induced concentra-
tion-dependent migration of BV 2 microglia, and was
more efficacious than previously described cannabinoid
ligands (Fig 2A). A ~50-fold greater concentration of 2-
AG than NAGly was required to reach the half-maximal
response of 2-AG; and in terms of AEA, a ~1000-fold
greater concentration of AEA than NAGly was required
to reach the half-maximal response of AEA.
Microglia in the adult CNS derive chiefly from a self-
renewing population or rarely are replenished from adult
bone marrow [31]. As they invade an injured region of the
CNS, microglia can enter the cell cycle and proliferate via
mitosis [5], e.g. elevated numbers of microglia are found
i n  b r a i n s  o f  p a t i e n t s  w i t h  m u l t i p l e  s c l e r o s i s  [ 3 3 ] ,
Alzheimer's disease [34] and HIV [35]. The reduction of
tetrazolium salts is widely accepted as a reliable way to
examine cell proliferation. In the MTT reduction tech-
nique, the yellow tetrazolium 3-(4,5-dimethyl-thiazoyl-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) is reduced
by metabolically active cells, in part by the action of dehy-
drogenase enzymes, to generate reducing equivalents
such as NADH and NADPH. The resulting intracellular
purple formazan dye can be solubilised and quantified by
spectrophotometric means. Using this means to quantify
Figure 1 NAGly-induced directed BV-2 microglial migration. (A) 
BV-2 microglial migration in response to basal conditions; vh (0.1% 
DMSO); 1 μM fMLP; 1 μM LPA; 0.1 nM - 300 μM NAGly. * = P < 0.05, ** = 
P < 0.01 compared to 1 μM fMLP; one-way ANOVA; n = 8. Insert is a filter 
photograph of one random field of view at ×40 magnification indicat-
ing the migration produced by 100 nM NAGly. The 10 μm diameter 
pores can be discerned as the clear unstained circles. (B) BV-2 microgli-
al migration in response to basal conditions; vh (0.1% DMSO); 1 μM 
fMLP ± concentration gradient; 0.1 nM - 10 μM NAGly ± concentration 
gradient. ** = P < 0.01 compared to the corresponding concentration 
gradient; Student's unpaired t-test; n = 3. Insert is a filter photograph of 
one random field of view at ×40 magnification indicating the migra-
tion produced by 100 nM NAGly in the absence of a concentration gra-
dient.
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cell proliferation in response to NAGly, AEA and 2-AG,
we found that NAGly increased the population of BV-2
microglia at picomolar to low nanomolar concentrations
after 24 hours (Figure 3A). The rank order of potency was
NAGly > 2-AG > AEA at stimulating BV-2 cell prolifera-
tion: a ~50% increase was achieved by 10 nM NAGly,
which was significantly greater than the ~24% and ~21%
seen with 10 nM AEA and 2-AG, respectively (P < 0.01;
one-way ANOVA; n = 3) (Figure 3A). Decreased cell via-
bility was observed for all three compounds at concentra-
tions greater than 1 μM. Carrier et al had previously
shown that 2-AG, but not AEA, exerted a M-CSF (mac-
rophage-colony stimulating factor) dependent prolifera-
tive effect on rat RTMGL1 microglia via CB2 receptors
Figure 2 NAGly-induced BV-2 microglial migration is concentra-
tion- and structure-dependent. (A) BV-2 microglial migration in re-
sponse to 0.1 nM - 10 μM concentrations of NAGly; AEA; 2-AG; PEA; 
PALGly; Abn-CBD; O-1602; LPI; n = 3. (B) Filter photographs of one ran-
dom field of view at ×40 magnification indicating the migration pro-
duced by 10 μM concentrations of NAGly, O-1602, 2-AG, Abn-CBD, AEA 
and LPI.
Figure 3 NAGly-induced BV-2 cell proliferation and MAPK en-
zyme activation. (A) BV-2 microglial proliferation in response to 0.01 
nM - 100 μM concentrations of NAGly; AEA; 2-AG; n = 3. (B) p44/42 
MAPK activation in BV-2 microglia in response to vh (0.1% DMSO) for 3 
hours; 10 nM - 10 μM NAGly for 3 hours; 10 μM Ionomycin for 5 min. ** 
= P < 0.01 compared to vh; one-way ANOVA; n = 3. (C) p38 MAPK acti-
vation in BV-2 microglia in response to vh (0.1% DMSO) for 3 hours; 10 
nM - 10 μM NAGly for 3 hours; 10 μM Ionomycin for 5 min. ** = P < 0.01 
compared to vh; one-way ANOVA; n = 3. (D) JNK MAPK activation in BV-
2 microglia in response to vh (0.1% DMSO) for 3 hours; 10 nM - 10 μM 
NAGly for 3 hours; 10 μM Ionomycin for 5 min. ** = P < 0.01 compared 
to vh; one-way ANOVA; n = 3.
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[36]. They observed ~30% increase with 300 nM 2-AG 24
hours after treatment, and this was accompanied by an
increase in active p44/42 MAPK (a.k.a. ERK1/2). MAPKs
respond to extracellular stimuli/mitogens and regulate
activities such as cell proliferation, differentiation, motil-
ity, and death. As migration is an activated-MAPK-
dependent phenomenon and 'Abn-CBD' receptors have
been shown to induce p44/42 MAPK phosphorylation
[13,19], we investigated the effect of NAGly on p44/42,
p38 and JNK MAPK enzymes using In-Cell Western
assays (Figures 3B, C &3D). NAGly induced a marked
concentration-dependent phosphorylation of p44/42 and
JNK MAPK (Figure 3B &3D), reflecting activation of
these kinases, whereas, p38 MAPK was only significantly
activated by 10 nM NAGly (Figure 3C). Our findings
extend those of Carrier et al, showing that NAGly, 2-AG
and AEA independently induce BV-2 microglial mitosis,
with NAGly being the most potent of the three. Given the
association between cell migration and proliferation, and
that both are MAPK-dependent, 'Abn-CBD' receptor-
activated phosphorylation of p44/42 and JNK MAPK in
response to NAGly likely underlies the migratory and
proliferative phenomena in BV-2 microglia.
In summary, the rank order of chemotactic potency
published by Walter (2003) for BV-2 microglia was largely
reproduced here. They found 2-AG > AEA > Abn-CBD at
inducing migration, while PEA caused a weak concentra-
tion-independent response [13]. Here we report, NAGly
> O-1602 > 2-AG > Abn-CBD > AEA, and the effects of
PEA, LPI and PALGly were weak and concentration-
independent (Figure 2A). NAGly is the most potent pro-
migratory lipid for BV-2 microglia cells described to date,
triggering directed migration and proliferation via MAPK
activation (Figures 1, 2 &3).
NAGly acts via a Gi/o-coupled GPCR
NAGly-stimulated BV-2 microglial migration was con-
centration- and structure-dependent (Figures 1A &2A),
implying a receptor-mediated mechanism. In light of the
known importance of engaging CB2  and 'Abn-CBD'
receptors to trigger BV-2 migration [13], the relationship
of these receptors to NAGly-induced BV-2 migration was
investigated. The role of CB1  and CB2  receptors was
examined using the antagonists/inverse agonists, rimona-
bant and SR144528. Rimonabant and SR144528 can block
non-CB1 and non-CB2 targets when administered at con-
centrations greater than their Kd values, i.e. in the micro-
molar range [13,36]. Therefore, 100 nM and 1 μM
rimonabant was used with the aim of distinguishing
between a CB1 or a non-CB1 rimonabant-sensitive ecep-
tor; while 100 nM SR144528 was used to maintain CB2
selectivity. Neither concentration of rimonabant had an
effect upon NAGly-induced migration, whereas
SR144528 caused ~63.5% inhibition of the response to 1
μM NAGly (Figure 4A). However, NAGly does not dem-
onstrate binding activity at either CB1 or CB2 receptors
[25]. An alternative explanation is that SR144528 is
exhibiting inverse agonism at constitutively active CB2
receptors [37] or blocking CB2  receptors involved in
transactivation. This hypothesis is reasonable given that
dual recruitment of CB2  and 'Abn-CBD' receptors is
required for 2-AG-induced BV-2 migration [13], and
SR144528 effects on constitutively active CB2  are
observed in other migratory immune cells [17]. To test
this, BV-2 microglia were pre-treated with 100 nM
SR144528 before attempting to induce migration with 1
μM fMLP. fMLP is a tripeptide chemoattractant released
from both bacteria and damaged mitochondria [38,39],
and activates two formyl peptide receptors, designated
Figure 4 NAGly-induced BV-2 microglial migration is Gi/o-recep-
tor mediated and can be antagonized. (A) BV-2 microglial migration 
in response to basal conditions; vh (0.1% DMSO); 1 μM fMLP; 1 μM fMLP 
+ 100 nM SR144528; 1 μM NAGly; 1 μM NAGly + 1 μM SR141716A; 1 μM 
NAGly + 100 nM SR141716A; 1 μM NAGly + 100 nM SR144528;. ** = P 
< 0.01 compared to 1 μM NAGly; tt = P < 0.01 compared to 1 μM fMLP; 
Student's unpaired t-test; n = 3. (B) BV-2 microglial migration in re-
sponse to 0.1 nM - 10 μM NAGly ± 1 μM O-1918, ± 1 μM ARA-S, or ± 24 
h pre-treatment with 1 μg/ml PTX; n = 3.
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FPR and FPRL-1 [40]. SR144528 caused ~32.2% inhibi-
tion of the response to 1 μM fMLP (Figure 4A). The esti-
mated percentage viability ± 100 nM SR144528 was 97.3
± 0.62 and 97.1 ± 0.67%, respectively; these values were
not significantly different (P > 0.05; Student's unpaired t-
test; n = 3), excluding cell death as a factor. Additionally,
in subsequent experiments with HEK293 cells, which do
not express CB2  receptors, we found that 100 nM
SR144528 had no effect on HEK293 cells stably trans-
fected with GPR18 induced in response to 1 μM NAGly;
the migration being 497 ± 8 cells and 501 ± 11 cells in the
presence and absence of SR144528 respectively (P > 0.05;
Student's unpaired t-test; n = 3). These data instead infer
a role for tonic CB2 signaling or transactivation in the
migratory mechanism. Interactions among GPCRs are
complex [41] and they have a propensity to experience
cross-talk when co-expressed, e.g. receptor dimerization
or heterologous desensitization. Thus, CB2 may cross-
modulate with fMLP receptors and the Gi/o receptor tar-
geted by NAGly to regulate migration in BV-2 microglia.
In summary, there is no evidence of a role for CB1, which
is consistent with the low levels of CB1 gene product pre-
viously observed in BV-2 microglia [42]. While CB2 is
demonstrably involved in BV-2 migration, it remains
questionable that NAGly is signaling directly via CB2
receptors.
With regard to 'Abn-CBD' receptors, the agonist profile
we observed with BV-2 migration was consistent with
that known for this novel receptor, i.e. Abn-CBD, AEA, 2-
AG and O-1602 stimulate migration (Figure 2A)
[13,15,16,18,22,43]. However, 1 μM rimonabant failed to
attenuated the NAGly response despite a reported IC50
value of 600 nM toward 'Abn-CBD' receptors (Figure 4A)
[18]. Whether or not total block with 1 μM rimonabant
should be expected in this circumstance would depend
on the affinity of NAGly for the receptor, the concentra-
tion of NAGly employed and the number of 'Abn-CBD'
receptors that need to be activated to see signaling; infor-
mation that is not yet available. As a consequence, we fur-
ther probed the role of 'Abn-CBD' receptors by
investigating the antagonistic effects of ARA-S and O-
1918 on NAGly- and fMLP-induced migration. In the
presence of 1 μM ARA-S or 1 μM O-1918, the migration
induced by NAGly was significantly attenuated (Figure
4B), whereas the migration in response to fMLP
remained unaffected; 100.0% ± 3.5% (1 μM fMLP alone),
101.2% ± 2.9% (1 μM fMLP + 1 μM ARA-S), 100.8% ±
3.14% (1 μM fMLP + 1 μM O-1918). These values were
not significantly different, P > 0.05; one-way ANOVA; n =
3. Likewise, neither ARA-S nor O-1918 had any effect on
basal BV-2 cell migration; 0.0% ± 2.1% (Vh alone), 0.3% ±
1.9% (Vh + 1 μM ARA-S), 0.2% ± 2.3% (Vh + 1 μM O-
1918). Similarly, these values were not significantly differ-
ent, P > 0.05; one-way ANOVA; n = 3.
Since NAGly activates Gi/o-coupled GPR18 and Gq/11-
coupled GPR92 [26,27], we investigated the effect of per-
tussis toxin (PTX) on the NAGly migratory response.
PTX pre-treatment abolished the migration to NAGly
(Figure 4B), without affecting cell viability. Using the try-
pan blue exclusion method, the estimated percentage via-
bility of cells pre-treated for 24 hours was not different (±
1 μg/ml PTX was 97.8 ± 0.47 and 97.4 ± 0.51%, respec-
tively; these values were not significantly different, P >
0.05; Student's unpaired t-test;  n  = 3). Taken together
these data indicate Gi/o GPCR involvement, and support
the hypothesis that NAGly is acting via the 'Abn-CBD'
GPCR to induce BV-2 microglial migration.
BV-2 microglia express both GPR18 mRNA and GPR18 
receptors
Our working hypothesis is that GPR18 is the 'Abn-CBD'
receptor and that its activation by NAGly is a highly
potent stimulation for microglial migration. For this to
hold true, BV-2 microglia must express GPR18 receptors.
Indeed, qPCR demonstrates that BV-2 and primary
microglia express abundant amounts of GPR18 mRNA
(Figures 5A &5B). In addition, immunocytochemical
Figure 5 BV-2 microglia express GPR18 mRNA and GPR18 recep-
tors. (A) Gel electrophoresis of BV-2 microglia and HEK293-GPR18 RT-
qPCR products. RT-qPCR products were collected from the RT-qPCR 
run, loading buffer was added to the samples, and samples were run 
on a 2% agarose gel. No template control (NTC) and a control without 
reverse transcription (NRT) were used as controls. (B) Representative 
qPCR amplification curves showing the different amounts of mRNAs 
for GPR18 in primary microglia and BV-2 cells; n = 3.
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staining revealed GPR18 receptors are expressed in a het-
erogeneous punctuate pattern throughout BV-2 micro-
glia and HEK293 cells stably transfected with GPR18,
including their polymerized lamellipodia [44,45] (Figure
6). Lamellipodia are cytoskeletal actin protrusions on the
mobile edge of a cell, believed to be both a steering device
and the actual motor that pulls the cell forward during
the process of chemotaxis [46-50]. Microglia adopt an
amoeboid-like form and extend such motile lamellipodia,
in order to achieve directed migration, enabling them to
move toward relevant CNS locations and affect appropri-
ate responses [51-54]. These data support our hypothesis
that GPR18 mediates NAGly-induced directed migration
of microglia.
Overexpression of GPR18 affects directed migration 
induced by NAGly and Abn-CBD
To further examine the hypothesis that NAGly is acting
through GPR18 to mediate its migratory effects in BV-2
microglia, and in light of there being no known GPR18
antagonists, we modelled BV-2 microglial migratory
observations using wildtype or HEK293 cells stably trans-
fected with HA11-tagged GPR18 (HEK293-GPR18).
NAGly elicited a concentration-dependent migratory
response in HEK293-GPR18 but not wildtype cells (Fig-
ures 7A &7B), with an Emax similar to BV-2 microglia. 24
h pre-treatment with PTX abolished the response to 1
μM NAGly, the mean number of cells migrated with and
without PTX pre-treatment was 505 ± 11 and 2 ± 1
respectively; these values were significantly different (P >
0.05; Student's unpaired t-test;  n  = 3). 1 μM NAGly-
induced migration was also significantly attenuated in the
presence of 1 μM O-1918 or 1 μM ARA-S (Figure 7C).
Abn-CBD and O-1602 also induced migration in
HEK293-GPR18 cells, with O-1602 being more potent
than Abn-CBD (Figure 7C); both responses were signifi-
cantly inhibited in the presence of 1 μM ARA-S or 1 μM
O-1918 (Figure 7C), which again is in agreement with the
BV-2 microglial data. CBD is known to behave as a partial
agonist/antagonist of 'Abn-CBD' receptors depending on
Figure 6 BV-2 microglia and HEK293-GPR18 transfected, but not 
HEK293 wildtype, cells express GPR18. Immunofluorescent confo-
cal microscopy was conducted using an antibody against the GPR18 
C-terminus (1:150; green), phalloidin to label actin (1:40; red), and DAPI 
(1.5 μg/ml) to label the nucleus (blue). a, HEK293 wildtype with DAPI 
and phalloidin. b, HEK293 wildtype with GPR18 antibody and phalloi-
din. c, HEK293 wildtype with GPR18 antibody, DAPI, and phalloidin. d, 
HEK293-GPR18 transfected with DAPI and phalloidin. e, HEK293-GPR18 
transfected with GPR18 antibody and phalloidin. f, HEK293-GPR18 
transfected with GPR18 antibody, DAPI, and phalloidin. g, BV-2 micro-
glia with DAPI and phalloidin. h, BV-2 microglia with GPR18 antibody 
and phalloidin. i, BV-2 microglia with GPR18 antibody, DAPI, and phal-
loidin.
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Figure 7 NAGly-induced migration of HEK293-GPR18 and 
HEK293-GPR55 cells. (A) HEK293 wildtype and HEK293-GPR18 trans-
fected cell migration in response to 0.1 nM - 10 μM NAGly; n = 3. (B) Fil-
ter photographs of one random field of view at ×40 magnification 
indicating the migration produced by 10 μM concentrations of NAGly 
in HEK293-GPR18 and HEK293 wildtype cells. The 10 μm diameter 
pores can be discerned as the clear unstained circles. (C) HEK293-
GPR18 cell migration in response to Vh (0.1% DMSO); 1 μM NAGly; 1 μM 
NAGly ± 1 μM O-1918; 1 μM NAGly ± 1 μM ARA-S. *** = P < 0.001 com-
pared to 1 μM NAGly; one-way ANOVA; n = 3. HEK293-GPR18 cell mi-
gration in response to 1 μM Abn-CBD; 1 μM Abn-CBD ± 1 μM O-1918; 
1 μM Abn-CBD ± 1 μM ARA-S; ttt = P < 0.001 compared to 1 μM Abn-
CBD; n = 3. HEK293-GPR18 cell migration in response to 1 μM O-1602; 
1 μM O-1602 ± 1 μM O-1918; 1 μM O-1602 ± 1 μM ARA-S. §§§ = P < 
0.001 compared to 1 μM O-1602; one-way ANOVA; n = 3. (D) BV-2 mi-
croglia and HEK293-GPR18 cell migration in response to Vh (0.1% DM-
SO); 1 μM NAGly; 1 μM NAGly = 1 μM CBD; *** = P < 0.001 compared 
to 1 μM NAGly; one-way ANOVA; n = 3. (E) p44/42 MAPK activation in 
HEK293-GPR18 cells in response to vh (0.1% DMSO) for 3 hours; 10 nM 
- 10 μM NAGly for 3 hours; 10 μM Ionomycin for 5 min. ** = P < 0.01 
compared to vh; one-way ANOVA; n = 3. (F) HEK293-GPR55 cell migra-
tion in response to 0.1 nM - 10 μM concentrations of LPI, Abn-CBD, 
NAGly, O-1602 and Vh (0.1% DMSO); n = 3.
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receptor expression levels [13,17]. 1 μM NAGly-induced
migration of both BV-2 microglia and HEK293-GPR18
receptors was also significantly attenuated in the pres-
ence of 1 μM CBD (Figure 7D). The NAGly-induced p44/
42 MAPK activation observed with BV-2 microglia too
was reproduced in HEK293-GPR18 cells (Figure 7E).
Several publications have suggested the orphan recep-
tor GPR55 interacts with certain cannabinoid ligands,
including Abn-CBD and O-1602 [55]. While this proposi-
tion remains a contentious one, BV-2 microglia do
express GPR55 mRNA [42]. Therefore we explored
whether NAGly, Abn-CBD, O-1602 or LPI stimulate
migration in HEK293 cells stably transfected with HA11-
tagged GPR55 (HEK293-GPR55). All four of these com-
pounds produced a weak, concentration-independent
migratory response in HEK293-GPR55 cells (Figure 7F)
that was irreconcilable with the NAGly, Abn-CBD and O-
1602 effects on BV-2 migration.
Discussion
'Abn-CBD' receptors have primarily been characterized
in vascular tissue and microglia. Studies investigating the
vasodilatory effects of AEA in CB 1/CB2 knockout mice
led to the postulation of the 'Abn-CBD' receptor as a
novel endothelial cannabinoid target for which AEA,
Abn-CBD and O-1602 were agonists that induced relax-
ation of the whole mesenteric arterial system [18]. Subse-
quent investigations have elaborated that multiple
signaling pathways underlie the hemodynamic effects
elicited by AEA, and involve CB1, TRPV1, 'Abn-CBD'
receptors and perhaps another distinct endothelium-
independent Abn-CBD/O-1602-sensitive target
[22,56,57]. The specifics vary according to particular
location in the vascular network and the preparation
under scrutiny, e.g. aorta vs mesenteric artery segments,
endothelium-intact vs endothelium-denuded vessels
[18,19,22,58]. In 2003, well-executed studies with pri-
mary and BV-2 microglia reproduced the pharmacology
of the endothelial 'Abn-CBD' receptor, revealing its
expression and significant migratory role in microglia
[13].
As a whole the cannabinoid field has eagerly awaited
developments that will clarify the molecular identity of
the 'Abn-CBD' receptor. Our analyses demonstrate that
NAGly and Abn-CBD regulate cellular migration through
GPR18, and we propose this GPCR is the unidentified
'Abn-CBD' receptor. Multiple lines of evidence substanti-
ate this hypothesis: NAGly, at sub-nanomolar concentra-
tions, together with the 'Abn-CBD' receptor agonists
Abn-CBD and O-1602 [15,16,18], potently drives cellular
migration in both BV-2 microglial and HEK293-GPR18
transfected cells, but not in HEK293-GPR55 or non-
transfected HEK293 cells. O-1602 was ~50 times more
effective than Abn-CBD at inducing migration in BV-2
microglia. This is in keeping with the work of Jarái et al
which first characterized 'Abn-CBD' receptors in the rat
mesenteric bed, where O-1602 was ~80 times more
potent than Abn-CBD at causing vasodilation [18]. 'Abn-
CBD' receptors couple via Gi/o proteins [13]; here, PTX
pre-treatment to uncouple such Gi/o proteins prevented
the migratory response to NAGly in BV-2 and HEK293-
GPR18 cells. The NAGly-, Abn-CBD-, and O-1602-
induced migration was blocked or attenuated in BV-2 or
HEK293-GPR18 cells by the 'Abn-CBD' receptor antago-
nist O-1918, and low efficacy agonists ARA-S and CBD.
NAGly promotes proliferation and activation of MAPK
enzymes at low nanomolar concentrations in BV-2 cells
and HEK293-GPR18 cells, demonstrating cellular
responses correlated with microglial migration and previ-
ous 'Abn-CBD' receptor activity on p44/42 MAPK
[13,19]. Finally, BV-2 microglia show heterogeneous
GPR18 immunocytochemical staining, including the
polymerized actin-containing lamellipodia that permit
motile cells to achieve directed migration, and abundant
GPR18 mRNA. qPCR demonstrates that primary micro-
glia, likewise, express abundant amounts of GPR18
mRNA.
Both the academic community and pharmaceutical
industry are engaged in intensive research of the endoge-
nous cannabinoid signaling system, focussing on its
potential therapeutic exploitation regarding mental ill-
ness, neuropathic and inflammatory pain, obesity, osteo-
porosis, nicotine addiction, cardiovascular disorders, and
liver disease. Therefore, our recognition of GPR18 as the
unidentified 'Abn-CBD' receptor has far-reaching impli-
cations. Firstly, hitherto unrecognized GPR18-mediated
effects by cannabinoid ligands, particularly those that
were previously classified as CB1- or CB2-receptor-selec-
tive, may have resulted in the misinterpretation of the
role of those receptors in various systems. Secondly, our
present definition and understanding of the endogenous
cannabinoid signaling system will have to be expanded
given the recognition of GPR18 as the 'Abn-CBD' recep-
tor and that its endogenous ligand, NAGly, is a metabolic
product of AEA [25]. Thirdly, elucidation of GPR18's
other physiological roles will further reveal the molecular
mechanisms responsible for the detrimental and medici-
nal effects of cannabis constituents. Lastly, GPR18-selec-
tive ligands will make available novel therapeutic routes
targeting a broad spectrum of pathophysiologies.
With specific regard to the CNS, microglia represent a
major cellular component of the brain, constituting a
widely distributed network of immunoprotective cells
[59,60]. During the last decades, it has become clear that
the roles traditionally ascribed to microglia, i.e. to dispose
of dead cells and debris and to mediate brain inflamma-
tory states, are only a fraction of a much wider repertoireMcHugh et al. BMC Neuroscience 2010, 11:44
http://www.biomedcentral.com/1471-2202/11/44
Page 9 of 13
of functions spanning from brain development to aging
and neuropathology [61,62]. Such functions are necessar-
ily reliant upon the complex signaling systems subserving
the reciprocal communication that occurs between neu-
rons and microglia [63]. Indeed, the loss of specific com-
munication between damaged neurons and microglia is
viewed as responsible for the turning of microglia to a
hyperactivated state, which allows them to escape neu-
ronal control and to give rise to persistent inflammation,
resulting in exacerbation of neuropathology [60].
Conclusions
The marked potency of NAGly acting on GPR18 to elicit
directed migration, proliferation and perhaps other
MAPK-dependent phenomena advances our understand-
ing of the lipid-based signaling mechanisms employed by
the CNS to actively recruit microglia to sites of interest. It
offers a novel research avenue for developing therapeu-
tics to elicit a self-renewing population of neuroregenera-
tive microglia, or alternatively, to prevent the
accumulation of misdirected, pro-inflammatory micro-
glia which contribute to and exacerbate neurodegenera-
tive disease.
Methods
Cells in culture
The mouse microglial cell line BV-2 (a gift from Dr. N.
Stella; University of Washington, Seattle), which was
originally generated by immortalizing primary microglia
(Blasi et al., 1990), were grown in high glucose DMEM
(Gibco, USA) supplemented with FBS (10%), penicillin
(100 units/ml), streptomycin (100 μg/ml), and passaged
every 4-5 days for a maximum of 30 passages. HEK293
wildtype (ATCC, USA), HEK293 cells stably transfected
with HA11-tagged GPR55 (HEK293-GPR55; previously
generated [64]) and HEK293 cells stably transfected with
HA11-tagged GPR18 (HEK293-GPR18; generated for
this study), were grown in Eagle's MEM (Gibco, USA)
supplemented with FBS (10%), penicillin (100 units/ml),
streptomycin (100 μg/ml) and L-glutamine (0.292 mg/
ml), and passaged every 4-5 days for a maximum of 30
passages. HEK293 cells were transfected with 2 μg of
HA11-tagged hGPR18 plasmid using Lipofectamine and
Plus reagents (Invitrogen, USA) in a 6-well plate using
standard molecular biological techniques [65]. G418-
resistant colonies were used as a positive control to vali-
date the specificity of the hGPR18-CT purified antibody.
In order to obtain primary microglia for the RNA
extraction studies, mixed glial cells were isolated from
dissociated cerebral cortex of newborn (P0-P1) C57BL/6J
mice as previously described [66]. The cell suspension
was prepared in culture medium for glial cells [DMEM
supplemented with 10% FCS, L-glutamine (1 mM),
sodium pyruvate (1 mM), penicillin (100 U/ml), and
streptomycin (100 mg/ml)] and cultured at 37°C/5% CO2
in 75-cm2 Falcon tissue-culture flasks, coated with polyD-
lysine (PDL). Half of the medium was changed after the
first day and every second day thereafter, for a total cul-
ture time of 10-14 days. Microglia were shaken off the
primary mixed brain glial cell cultures (150 rpm for 4-6 h
at 37°C), with maximal yields between days 10 and 14.
Cells were seeded onto PDL-pretreated 60 mm plates and
grown in culture medium for microglia [RPMI medium
supplemented with 10% FCS, L-glutamine (1 mM),
sodium piruvate (1 mM), penicillin (100 U/ml) and strep-
tomycin (100 mg/ml). The cells were allowed to adhere to
the PDL-coated plate (30 min, 37°C/5% CO2) and the
nonadherent cells were rinsed off. After 48 h microglial
cells are ready to be used for experiments.
Test compounds
Appropriate stock concentrations of the compounds
tested in this study were prepared in 100% DMSO, before
being serially diluted to achieve the desired final working
concentrations, each containing 0.1% DMSO as vehicle.
Lipid ligands were purchased from Enzo Life Sciences
(Farmingdale, NY 11735) with the exception of O-1602,
O-1918, and Abn-CBD, which were purchased from Cay-
man Chemicals (Ann Arbor, Michigan 48108).
Migration assay
In vitro cell migration assays were performed using a
modified 96-well Boyden Chamber and PVP-free poly-
carbonate filters with 10 μm diameter pores (Neuroprobe
Inc., USA), which can be discerned as the clear unstained
circles in the photographed filters of figures 1 &6. The
upper wells of the Boyden chamber were filled with 50 μl
of suspension of 1 × 106 cells ml-1 in serum-free DMEM,
before incubation with a 5% CO2 atmosphere at 37°C for
3 hours. 1 μM fMLP acted as positive control. Following
incubation, non-migrated cells were then removed before
fixation and staining with Diff-Quik® stain set. Finally, the
filter was sectioned and mounted onto microscope slides
and the migrated cells counted in ten non-overlapping
fields (×40 magnification) with a light microscope by
multiple scorers blinded to experimental conditions. For
inhibition of induced migration, cells were pre-incubated
with antagonist for 30 min at 37°C in a water bath before
loading into the upper wells, the lower wells contained
the equivalent concentration of antagonist and test com-
pound to ensure that the only concentration gradient
present is that generated by the test compound as they
diffuse through the pores in the filter.
Cell proliferation assay
BV-2 cells were plated in 96-well plates at a seeding den-
sity of 1 × 104 cells per well overnight in media containing
1% FBS. The media was then changed to fresh media con-McHugh et al. BMC Neuroscience 2010, 11:44
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taining 1% FBS and the appropriate concentrations of test
compound, then incubated for 24 hours. Cell density was
assessed with the 3-(4,5-dimethyl-thiazoyl-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) formazan dye con-
version assay (ATCC, USA) according to the manufac-
turer's instructions and measured at 570 nm with a
SpectraMax M5 spectrophotometer (Molecular Devices,
USA).
In-Cell Western assay
An In-Cell Western assay was employed to simultane-
ously detect both the phosphorylated MAPK protein and
normalize for total MAPK protein. The following pri-
mary antibodies were used to detect endogenous levels of
the relevant total MAPK and phosphorylated MAPK:
p44/42 MAPK rabbit pAb, and phospho-p44/42 MAPK
mouse mAb (#4695 and #9106; Cell Signaling Technol-
ogy, USA); p38 MAPK rabbit pAb, and phosphor-p38
MAPK mouse mAb (#9212 and #9216; Cell Signaling
Technology, USA); and SAPK/JNK MAPK rabbit pAb,
and phospho-SAPK/JNK MAPK mAb (#9252 and #9255;
Cell Signaling Technology, USA).
BV-2 cells were plated into 96-well plates coated with 1
μg ml-1 poly-L-lysine and treated with vehicle (Vh) (0.1%
DMSO) or NAGly (10 nM - 10 μM) for 3 hours. Ionomy-
cin (10 μM) treatment in the final 5 min was used as a
positive control. Upon completion of the drug treat-
ments, an In-cell Western assay was conducted: the 96-
w e l l  p la t e s  w e r e  i m m ed i a t e l y  p la c ed  o n  i c e ,  t h e  m ed i a
removed and cells fixed with 100 μl/well of 3.7% formal-
dehyde in PBS for 15 min. The 96-well plates were then
removed from the ice and allowed to warm up to room
temperature over 30 min. The formaldehyde solution was
replaced by 100 μl/well of ice-cold methanol and the plate
kept at -20°C for 20 min. The cells were washed with 200
μl of 0.1% Triton X-100 in PBS with gentle shaking for 5
min at room temperature, the wash solution was
removed before adding fresh 0.1% Triton X-100 and
repeating for a total of 5 times. Following the final wash,
cells were blocked with 150 μl of Odyssey blocking buffer
(Li-Cor, USA) with moderate shaking for 90 min at 20°C.
Primary antibody pairs (e.g. p44/42 and phospho-p44/42
MAPK) were diluted in Odyssey blocking buffer 1:200
and the plate was then incubated overnight with moder-
ate shaking at 4°C. Primary antibody solution or Odyssey
blocking buffer was then removed from all wells before
they were washed with 0.1% Tween-20 in PBS with mod-
erate shaking for 5 min at room temperature, this was
repeated for a total of 5 times. Fluorescently labelled sec-
ondary antibodies (Odyssey 926-32211 goat anti-rabbit
800 nm antibody; 926-32220 goat anti-mouse 680 nm
antibody; Li-Cor, USA) were diluted in Odyssey blocking
buffer 1:800 containing 0.2% Tween-20. The secondary
antibody solution was added to all wells and incubated in
the dark for 90 min at room temperature. Secondary anti-
body solution was removed and the wells then washed
with 0.1% Tween-20 in PBS with moderate shaking for 5
min at room temperature for a total of 5 times, while pro-
tecting from light. The final wash solution was removed
and discarded. The plate was then scanned using the Li-
Cor Odyssey Infrared Imaging System (Li-Cor, USA),
using both 700 and 800 nm channels, a resolution of 42
μm, quality set to high, an intensity of 5, and focal offset
of 4 mm.
Using the Odyssey application software, changes in
M A P K  a c t i v a t i o n  w e r e  d e t e r m i n e d  b y  c a l c u l a t i n g  t h e
mean background fluorescence from all non-primary
antibody containing control wells, for both 700 and 800
nm channels. Background fluorescence was subtracted
from the fluorescence measured in primary antibody
containing wells, for both the 700 and 800 nm channels.
The relative intensity of phospho-MAPK fluorescence
was normalized against the relative intensity of fluores-
cence measured for total-MAPK. Finally the % response
of all test compounds relative to vehicle was determined.
Isolation of total RNA and real-time quantitative PCR 
(qPCR)
RNA was extracted from BV-2, HEK293-GPR18 trans-
fected cells, and primary microglial cells using the
RNAqueous® small scale phenol-free total RNA isolation
kit (Applied Biosystems, USA) and RNA samples (2 μg)
were reverse transcribed using the SuperScript II™
Reverse Transcription Kit (Invitrogen, USA).
Expression of GPR18 mRNA in BV-2 and primary
microglia was determined by RT-qPCR, using B2-MG as
a normalizing gene, as previously described [67]. Normal,
mock reversed transcribed samples (NRT), and no tem-
plate controls (NTC; total mix without cDNA) were run
f o r  e a c h  o f  t h e  e x a m i n ed  m RN As.  R T - q PCR  r ea ct i o n s
were subjected to an initial HotStar Taq (Qiagen, USA)
DNA polymerase activation step (15 min at 95°C), fol-
lowed by 40 cycles each consisting of 15 s at 94°C, 30 s at
60°C and 30 s at 72°C. Fluorescence was measured at the
end of each elongation step. Data were analyzed using the
Rotor-gene software (Corbett Research, Australia) and a
threshold cycle value Ct was calculated from the expo-
nential phase of each RT-qPCR sample. Amounts of
mRNA were calculated and expressed in relative units of
SYBR Green fluorescence. PCR products were analyzed
on a 2% agarose gel with ethidium bromide.
Expression of GPR18 in BV-2 microglia and HEK293-
GPR18 cells was also determined by PCR using oligonu-
cleotide primers based on the sequence of the Mus mus-
culus  G protein-coupled receptor 18 (GPR18) mRNA
(GenBank Accession No. NM_182806.1) and B2-MG
mRNA (GenBank Accession No. NM_009735). The
primer sequences used were forward, TGAAGCCCA-McHugh et al. BMC Neuroscience 2010, 11:44
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AGGTCAAGGAGAAGT and reverse, TTCATGAGGAA
GGTGGTGAAGGCT (amplicon 163 bp) for the GPR18
and forward, ATGGGAAGCCGAACATACTG and
reverse, CAGTCTCAGTGGGGGTGAAT (amplicon of
176 bp) for B2-MG. PCR reactions were subjected to an
initial HotStart Taq DNA polymerase activation step of
95°C for 7 minutes, followed by 40 cycles of 94°C for 30
seconds, 55°C for 30 seconds, and 72°C for 30 seconds.
PCR products were analyzed on a 2% agarose gel with
ethidium bromide. Single bands corresponding to 163 bp
for the GPR18 amplicon and 176 bp for the B2-MG ampl-
icon were recorded.
GPR18 antibody generation
A GST fusion protein expression construct was produced
by inserting the DNA coding for a C-terminal 29-aa pep-
tide (YRNYLRSMRRKSFRSGSLRSLSNINSEML) from
human G-protein-coupled receptor (hGPR18) into a
pGEX-3X vector at the BamH I and EcoR I restriction
sites. The fusion protein was purified from BL21 E. coli
lysates on a glutathione Sepharose column and was
injected into two rabbits to generate antisera (Cocalico
Biologicals, USA) using standard approaches [68]. The
antiserum was purified in two steps, first by exclusion on
a GST column and then by binding to and elution from
an affinity column made with the injected GST fusion
protein.
Immunocytochemistry
The GPR18 antibody generated for this study recognizes
hGPR18 receptors stably expressed in HEK293-GPR18
cells (Figure 8) and endogenous GPR18 in BV-2 microglia
(Figure 6). Cells were fixed with paraformaldehyde,
blocked, and stained as follows: polyclonal rabbit anti-C-
terminal GPR18 (1:150) (generated for this study) and
Texas Red-conjugated phalloidin (1:40; Molecular
Probes, Eugene, OR). Secondary IgG antibodies were
FITC-conjugated donkey anti-rabbit (1:150; Jackson
ImmunoResearch, USA). Images were acquired with a
Nikon Eclipse TE2000-E confocal microscope (Nikon,
USA).
Analysis of data
For BV-2 microglia, the mean number of cells migrated in
response to test compounds was normalized against the
mean number of migrated cells elicited by 1 μM fMLP
(0.1% DMSO). The number of migrated cells under vehi-
cle only conditions (0.1% DMSO) was subtracted.
For HEK293 wildtype and HEK293-GPR18 transfected
cells, simply the mean number of cells migrated above
vehicle only conditions was used. All data are expressed
as means ± s.e.mean and n  = number of independent
experiments. Statistical analyses were performed with
GraphPad Prism 4. Concentration-response curves were
generated using a sigmoidal dose-response (variable
slope) curve-fitting process, except for that representing
BV-2 cell proliferation where a simple point-to-point
curve fit was employed instead.
List of abbreviations
Abn-CBD: abnormal cannabidiol; ANOVA: analysis of
variance; AA: arachidonic acid; AEA: N-arachidonoyl
ethanolamine; 2-AG: 2-arachidonoyl glycerol; ARA-S: N-
arachidonoyl-L-serine; B2-MG: beta-microglobulin;
CBD: cannabidiol; CBN: cannabinol; CB1: cannabinoid
receptor 1; CB2: cannabinoid receptor 2; CNS: central
nervous system; DMEM: Dulbecco's Minimum Essential
Medium; DMSO: dimethyl sulphoxide; ERK1/2: extracel-
lular signal-regulated kinase 1/2; FAAH: fatty acid amide
hydrolase; FBS: fetal bovine serum; fMLP: N-formyl-
methionine-leucine-phenylalanine; GPCR: G protein-
coupled receptor; LPA: arachidonoyl lysophosphatidic
acid; LPI: L-α-lysophophatidylinositol; MAPK: mitogen-
activated protein kinase; M-CSF: macrophage-colony
stimulating factor; MTT 3-(4,5-dimethyl-thiazoyl-2-yl)-
2,5-diphenyltetrazolium bromide; NAGly: N-arachi-
donoyl glycine; NRT: normal, mock reverse transcribed
samples; NTC: total mix without cDNA; PTX: pertussis
toxin; O-1602: trans-4- [3-methyl-6-(1-methylethenyl)-2-
cyclohexen-1-yl]-5-methyl-1,3-benzenediol; O-1918: 1,3-
dimethoxy-5-methyl-2- [(1R,6R)-3-methyl-6-(1-methyle-
thenyl)-2-cyclohexen-1-yl)-benzene; PALGly: palmitoylg-
lycine; PEA: palmitoyl ethanolamine; Rimonabant (a.k.a.
Figure 8 GPR18 antibody recognizes hGPR18 receptors stably ex-
pressed in HEK293-GPR18 cells. Immunofluorescent confocal mi-
croscopy was conducted using HEK293 cells stably transfected with 
HA11-tagged hGPR18 and HA11 (1:500) and GPR18 (1:500) antibodies. 
a, HA11 antibody (detected with Texas Red secondary; red) staining 
shows HA11-hGPR18 transfected cells. b, hGPR18 antibody (detected 
with FITC secondary; green) staining of the same cells identified with 
the HA11 antibody. c, HA11 antibody (detected with Texas Red sec-
ondary; red) staining shows HA11-hGPR18 transfected cells. d, hGPR18 
antibody staining (detected with FITC secondary; green) was blocked 
when the GPR18 antibody was co-incubated with immunizing protein 
(30 μg/ml) for 1 hour before administration. DAPI (1.5 μg/ml; blue) was 
used to label the nucleus of all HEK293-GPR18 cells.
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SR141716A),  N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-
(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxim-
ide hydrochloride; RT-PCR: reverse transcriptase poly-
merase chain reaction; SR144528: 5-(4-chloro-3-
methylphenyl)-1-[(4-methylphenyl)methyl]-N--
[(1S,4R,6S)-1,5,5-trimethyl-6bicyclo[2.2.1]heptanyl]pyra-
zole-3-carboxamide.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DM performed the cell culture procedures, cell migration studies, cell prolifera-
tion experiments, In-Cell Western assays and immunocytochemistry imaging;
design and coordination of the studies; data interpretation; statistical analyses;
and manuscript preparation. NR PCR studies. AJ PCR studies. SSH generated
the hGPR18 antibody; immunocytochemistry imaging. ZV PCR studies. JWM
initial study design. HBB design and coordination of the studies, and manu-
script preparation. All authors read and approved the final manuscript.
Acknowledgements
We dedicate this manuscript to J. Michael Walker (1950-2008) whose love of 
science and generosity was an inspiration to us all. This work was supported by 
NIH DA018224 and DA011322, and the Weizmann Institute. NIH and the Weiz-
mann Institute had no role in the study design; in the collection, analysis and 
interpretation of data; in the writing of the manuscript; or in the decision to 
submit the manuscript for publication. DM, HBB and JMW were supported by 
DA018224; SS-JJ was supported by DA011322; and NR, AJ and ZV were sup-
ported by the Weizmann Institute. The manuscript preparation was funded by 
NIH DA018224. Imaging experiments were made possible by use of the shared 
Neuroscience MetaCyt core facility at Indiana University.  
Author Details
1The Department of Psychological and Brain Sciences, 1101 East 10th Street, 
Indiana University, Bloomington, IN 47405, USA, 2The Gill Center for 
Biomolecular Science, 1101 East 10th Street, Indiana University, Bloomington, 
IN 47405, USA, 3The Neurobiology Department, Weizmann Institute of Science, 
Rehovot, Israel and 4The Adelson Center for the Biology of Addictive Diseases, 
Sackler Faculty of Medicine, Tel Aviv University, Israel
References
1. Fetler L, Amigorena S: NEUROSCIENCE: Brain Under Surveillance: The 
Microglia Patrol.  Science 2005, 309:392-393.
2. Raivich G: Like cops on the beat: the active role of resting microglia.  
Trends Neurosci 2005, 28:571-573.
3. Block ML, Zecca L, Hong J-S: Microglia-mediated neurotoxicity: 
uncovering the molecular mechanisms.  Nat Rev Neurosci 2007, 8:57-69.
4. Trapp BD, et al.: Evidence for synaptic stripping by cortical microglia.  
Glia 55:360-368.
5. Garden GA, Moller T: Microglia biology in health and disease.  J 
Neuroimmune Pharmacol 2006, 1:127-137.
6. Gordon S: Alternative activation of macrophages.  Nat Rev Immunol 
2003, 3:23-35.
7. van Rossum D, Hanisch U-K: Microglia.  Metab Brain Dis 2004, 19:393-411.
8. Carson MJ: Microglia as liaisons between the immune and central 
nervous systems: functional implications for multiple sclerosis.  Glia 
2002, 40:218-231.
9. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, 
Veerhuis R, Williams A: Neuroinflammation in Alzheimer's disease and 
prion disease.  Glia 2002, 40:232-239.
10. Streit WJ: Microglia as neuroprotective, immunocompetent cells of the 
CNS.  Glia 2002, 40:133-139.
11. Danton GH, Dietrich WD: Inflammatory mechanisms after ischemia and 
stroke.  J Neuropathol Exp Neurol 2003, 62:127-136.
12. Franklin A, Stella N: Arachidonylcyclopropylamide increases microglial 
cell migration through cannabinoid CB2 and abnormal-cannabidiol-
sensitive receptors.  Eur J Pharmacol 2003, 474:195-198.
13. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N: 
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell 
Migration.  J Neurosci 2003, 23:1398-1405.
14. Brown AJ: Novel cannabinoid receptors.  Br J Pharmacol 2007, 
152:567-575.
15. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, 
Kunos G: Evidence for novel cannabinoid receptors.  Pharmacol Ther 
2005, 106:133-145.
16. Mackie K, Stella N: Cannabinoid receptors and endocannabinoids: 
Evidence for new players.  AAPS J 2006, 8:E298-E306.
17. McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA: Inhibition of 
human neutrophil chemotaxis by endogenous cannabinoids and 
phytocannabinoids: Evidence for a site distinct from CB1 and CB2.  Mol 
Pharmacol 2008, 73:441-450.
18. Járai Z, Wagner JA, Varga Kr, Lake KD, Compton DR, Martin BR, Zimmer 
AM, Bonner TI, Buckley NE, Mezey E, et al.: Cannabinoid-induced 
mesenteric vasodilation through an endothelial site distinct from CB1 
or CB2 receptors.  Proc Natl Acad Sci USA 1999, 96:14136-14141.
19. Offertáler L, Mo F-M, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski 
RD, Kunos G: Selective Ligands and Cellular Effectors of a G Protein-
Coupled Endothelial Cannabinoid Receptor.  Mol Pharmacol 2003, 
63:699-705.
20. Mo FM, Offertáler L, Kunos G: Atypical cannabinoid stimulates 
endothelial cell migration via a Gi/Go-coupled receptor distinct from 
CB1, CB2 or EDG-1.  Eur J Pharmacol 2004, 489:21-27.
21. Vaccani A, Massi P, Colombo A, Rubino T, Palolaro D: Cannabidiol inhibits 
human glioma cell migration through a cannabinoid receptor-
independent mechanism.  Eur J Pharmacol 489:21-27.
22. Wagner JA, Varga K, Jarai Z, Kunos G: Mesenteric Vasodilation Mediated 
by Endothelial Anandamide Receptors.  Hypertension 1999, 33:429-434.
23. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, Mo F-M, 
Offertaler L, Pacher P, Kunos G, et al.: N-arachidonoyl l-serine, an 
endocannabinoid-like brain constituent with vasodilatory properties.  
Proc Natl Acad Sci USA 2006, 103:2428-2433.
24. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R: Structural 
Requirements for Binding of Anandamide-Type Compounds to the 
Brain Cannabinoid Receptor.  J Med Chem 1997, 40:659-667.
25. Bradshaw H, Rimmerman N, Hu S, Benton V, Stuart J, Masuda K, Cravatt B, 
O'Dell D, Walker JM: The endocannabinoid anandamide is a precursor 
for the signaling lipid N-arachidonoyl glycine by two distinct 
pathways.  BMC Biochem 2009, 10:14.
26. Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, Yasukawa 
M: Identification of N-arachidonylglycine as the endogenous ligand for 
orphan G-protein-coupled receptor GPR18.  Biochem Biophyl Res Comm 
2006, 347:827-832.
27. Oh DY, Yoon JM, Moon MJ, Hwang J-I, Choe H, Lee JY, Kim JI, Kim S, Rhim 
H, O'Dell DK, et al.: Identification of Farnesyl Pyrophosphate and N-
Arachidonylglycine as Endogenous Ligands for GPR92.  J Biol Chem 
2008, 283:21054-21064.
28. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F: Immortalization of 
murine microglial cells by a v-raf/v-myc carrying retrovirus.  J 
Neuroimmunol 1990, 27:229-237.
29. Lorton D, Schaller J, Lala A, De Nardin E: Chemotactic-like receptors and 
Aβ peptide induced responses in Alzheimer's Disease.  Neurobiol Aging 
2000, 21:463-473.
30. Schilling T, Stock C, Schwab A, Eder C: Functional importance of Ca2+-
activated K+ channels for lysophosphatidic acid-induced microglial 
migration.  Eur J Neurosci 2004, 19:1469-1474.
31. Gao X, Hu X, Qian L, Yang S, Zhang W, Zhang D, Wu X, Fraser A, Wilson B, 
Flood PM, et al.: Formyl-methionyl-leucyl-phenylalanine-induced 
dopaminergic neurotoxicity via microglial activation: a mediator 
between peripheral infection and neurodegeneration?  Environ Health 
Perspect 2008, 116:593-598.
32. Puntambekar SS, Doose JM, Carson MJ: Microglia: A CNS-Specific Tissue 
Macrophage.  In Central Nervous System Diseases and Inflammation 
Springer NY; 2008:1-12. 
Received: 12 March 2010 Accepted: 26 March 2010 
Published: 26 March 2010
This article is available from: http://www.biomedcentral.com/1471-2202/11/44 © 2010 McHugh et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Neuroscience 2010, 11:44McHugh et al. BMC Neuroscience 2010, 11:44
http://www.biomedcentral.com/1471-2202/11/44
Page 13 of 13
33. Schönrock , Kuhlmann , Adler , Bitsch , Brück : Identification of glial cell 
proliferation in early multiple sclerosis lesions.  Neuropathol Appl 
Neurobiol 1998, 24:320-330.
34. Mackenzie IRA, Hao C, Munoz DG: Role of Microglia in Senile Plaque 
Formation.  Neurobiol Aging 1995, 16:797-804.
35. Gendelman H, Lipton S, Tardieu M, Bukrinsky M, Nottet H: The 
neuropathogenesis of HIV-1 infection.  J Leukoc Biol 1994, 56:389-398.
36. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, 
Pfister SL, Campbell WB, Hillard CJ: Cultured Rat Microglial Cells 
Synthesize the Endocannabinoid 2-Arachidonylglycerol, Which 
Increases Proliferation via a CB2 Receptor-Dependent Mechanism.  Mol 
Pharmacol 2004, 65:999-1007.
37. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, 
Oustric D, Sarran M, Bouaboula M, Calandra B, et al.: SR14 the first potent 
and selective antagonist of the CB2 cannabinoid receptor.  J Pharmacol 
Exp Ther 4528, 284:644-650.
38. Carp H: Mitochondrial N-formylmethionyl proteins as 
chemoattractants for neutrophils.  J Exp Med 1982, 155:264-275.
39. Chadwick VS, Mellor DM, Myers DB, Selden AC, Keshavarzian A, Broom MF, 
Hobson CH: Production of Peptides Inducing Chemotaxis and 
Lysosomal Enzyme Release in Human Neutrophils by Intestinal 
Bacteria in Vitro and in Vivo.  Scand J Gastroenterol 1988, 23:121-128.
40. Hartt JK, Barish G, Murphy PM, Gao J-L: N-formylpeptides Induce Two 
Distinct Concentration Optima for Mouse Neutrophil Chemotaxis by 
Differential Interaction with Two N-formylpeptide Receptor (FPR) 
Subtypes: Molecular Characterization of FPR2, a Second Mouse 
Neutrophil FPR.  J Exp Med 1999, 190:741-748.
41. Snyderman R, Uhing RJ: Chemoattractant stimulus-response coupling.  
In Inflammation: Basic Principles and Clinical Correlates Raven Press Lts. NY; 
1999:421-439. 
42. Pietr M, et al.: Differential changes in GPR55 during microglial cell 
activation.  FEBS let 583:2071-2076.
43. Showalter V, Compton D, Martin B, Abood M: Evaluation of binding in a 
transfected cell line expressing a peripheral cannabinoid receptor 
(CB2): identification of cannabinoid receptor subtype selective ligands.  
J Pharmacol Exp Ther 1996, 278:989-999.
44. Mitchison TJ, Cramer LP: Actin-Based Cell Motility and Cell Locomotion.  
Cell 1996, 84:371-379.
45. Watanabe N, Mitchison TJ: Single-Molecule Speckle Analysis of Actin 
Filament Turnover in Lamellipodia.  Science 2002, 295:1083-1086.
46. Alberts , Bruce : Molecular Biology of the Cell.  Fourth edition. Garland 
Science, Taylor & Francis Group. New York; 2002:908.  931, 973-975.
47. Sanchez-Madrid F, del Pozo MA: Leukocyte polarization in cell migration 
and immune interactions.  EMBO J 1999, 18:501-511.
48. Bokoch GM: Regulation of innate immunity by Rho GTPases.  Trends Cell 
Biol 2005, 15:163-171.
49. Xu J, Wang F, Van Keymeulen A, Herzmark P, Straight A, Kelly K, Takuwa Y, 
Sugimoto N, Mitchison T, Bourne HR: Divergent signals and cytoskeletal 
assemblies regulate self-organizing polarity in neutrophils.  Cell 2003, 
114:201-214.
50. Dong X, Mo Z, Bokoch G, Guo C, Li Z, Wu D: P-Rex1 is a primary Rac2 
guanine nucleotide exchange factor in mouse neutrophils.  Curr Biol 
2005, 15:1874-1879.
51. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS.  
Trends Neurosci 1996, 19:312-318.
52. Bruce-Keller AJ: Microglial-neuronal interactions in synaptic damage 
and recovery.  J Neurosci Res 1999, 58:191-201.
53. Becher B, Prat A, Antel JP: Brain-immune connection: immuno-
regulatory properties of CNS-resident cells.  Glia 2000, 29:293-304.
54. Stence N, Waite M, Dailey ME: Dynamics of microglial activation: a 
confocal time-lapse analysis in hippocampal slices.  Glia 2001, 
33:256-266.
55. Ross RA: The enigmatic pharmacology of GPR55.  Trends Pharmacol Sci 
2009, 30:156-163.
56. Zygmunt PM, Hogestatt ED: Role of potassium channels in 
endothelium-dependent relaxation resistant to nitroarginine in the rat 
hepatic artery.  Br J Pharmacol 1996, 117:1600-1606.
57. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR: 
Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to 
inhibit L-type Ca2+ channel current.  Am J Physiol Heart Circ Physiol 1999, 
276:H2085-2093.
58. Mukhopadhyay S, Chapnick BM, Howlett AC: Anandamide-induced 
vasorelaxation in rabbit aortic rings has two components: G protein 
dependent and independent.  Am J Physiol Heart Circ Physiol 2002, 
282:H2046-2054.
59. Vaughan DW, Peters A: Neuroglial cells in the cerebral cortex of rats 
from young adult to old age: an electron microscopy study.  J 
Neurocytol 1974, 3:405-429.
60. Banati R: Neuropathological imaging: in vivo detection of glial 
activation as a measure of disease and adaptive change in the brain.  
Brit Med Bul 2003, 65:121-131.
61. Innocenti GM, Clarke S, Koppell H: Transitory macrophages in the white 
matter of the developing visual cortex. II. Development and relations 
with axonal pathways.  Dev Brain Res 1983, 11:55-66.
62. Marin-Teva JL, Dusart I, Colin C, Gervais A, van Rooijen N, Mallat M: 
Microglia promote the death of developing purkinje cells.  Neuron 
2004, 41:535-547.
63. Polazzi E, Contestabile A: Reciprocal interactions between microglia and 
neurons: from survival to neuropathology.  Rev Neurosci 2004, 
13:221-242.
64. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K: GPR55 is a 
cannabinoid receptor that increases intracellular calcium and inhibits 
M current.  Proc Natl Acad Sci USA 2008, 105:2699-2704.
65. Daigle TL, Kearn CS, Mackie K: Rapid CB1 cannabinoid receptor 
desensitization defines the time course of ERK1/2 MAP kinase 
signaling.  Neuropharmacology 2008, 54:36-44.
66. Juknat AA, Kotler ML, Quaglino A, Carrillo NM, Hevor T: Necrotic cell 
death induced by delta-aminolevulinic acid in mouse astrocytes. 
Protective role of melatonin and other antioxidants.  J Pineal Res 2003, 
35:1-11.
67. Butovsky O, Landa G, Kunis G, Ziv Y, Avidan H, Greenberg N, Schwartz A, 
Smirnov I, Pollack A, Jung S, et al.: Induction and blockage of 
oligodendrogenesis by differently activated microglia in an animal 
model of multiple sclerosis.  J Clin Invest 2006, 116:905-915.
68. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N, Freund TF: 
Endocannabinoid signaling in rat somatosensory cortex: laminar 
differences and involvement of specific interneuron types.  J Neurosci 
2005, 25:6845-6856.
doi: 10.1186/1471-2202-11-44
Cite this article as: McHugh et al., N-arachidonoyl glycine, an abundant 
endogenous lipid, potently drives directed cellular migration through GPR18, 
the putative abnormal cannabidiol receptor BMC Neuroscience 2010, 11:44